The Lambda ZAP®-CMV vector for efficient library construction
and mammalian expression
A New Lambda Vector for Mammalian Expression
Quinn Lu • Tanya Hosfield • Cherie Dewar • Tim Sanchez
• Mike Kobrin
Stratagene
Stratagene’s new lambda cloning vector, the Lambda ZAP ®-CMV
vector,* contains the left and right arms of the Lambda ZAP II vector and
the pCMV-Script ® -EX phagemid vector. High-efficiency cDNA
libraries constructed in the Lambda ZAP-CMV vector can be converted to plasmid
libraries by a simple in vivo excision procedure. This vector preserves the
benefits of lambda library construction, while providing the convenience of
plasmids for expression in mammalian cells and characterization of cloned
inserts.
Stratagene’s family of Lambda ZAP vectors is designed to simplify the
construction of high-titer cDNA libraries and the characterization of inserted
DNA. These vectors are distinguished by their capability to easily excise and
recircularize cloned insert DNA from lambda phage. When either single clones or
the entire lambda library is converted to a plasmid format by in vivo excision,1-5
they combine the high-efficiency cloning of lambda vectors with the convenience
of plasmid libraries for functional studies. This elegant procedure requires
very little hands-on time and eliminates the need for subcloning procedures.
High-Level Expression in Mammalian Cells

Figure
1
Stratagene’s new lambda vector, the Lambda ZAP-CMV vector, offers
efficient library construction and, upon mass excision, high-level eukaryotic
expression in the pCMV-Script-EX phagemid vector. The Lambda ZAP-CMV vector
(Figure
1) contains lambda arms derived from the Lambda ZAP II vector, three
unique restriction sites in the multiple cloning site, and the pCMV-Script-EX
phagemid vector.

Figure
2
The pCMV-Script-EX vector contains 15 unique sites for cloning (Figure
2) and offers the same features as its parental pCMV-Script vector;6
gene expression driven by the CMV promoter for constitutive expression
in a wide variety of cell lines;### the SV40 polyadenylation
site; and the neomycin-resistance gene under control of the prokaryotic
b-lactamase promoter, to provide kanamycin
resistance in bacteria, as well as the SV40 early promoter, to provide
G418 resistance in mammalian cells. The pCMV-Script-EX vector varies from
its parental pCMV-Script vector by a 29-bp sequence downstream of the
f1 origin; however, this additional sequence is in a nonfunctional region
of the vector. Thus, the new pCMV-Script-EX vector is functionally equivalent
to the pCMV-Script vector.
The Lambda-ZAP CMV vector is available in kits of varying components to
accommodate different research needs. The Lambda ZAP-CMV XR library construction
kit includes the directional cDNA synthesis kit, the Lambda ZAP-CMV XR vector,
Gigapack® III Gold packaging extract, host strains, and helper
phage. Lambda ZAP-CMV vector kits are available that include the Lambda ZAP-CMV
vector predigested with either EcoR I only or EcoR I and Xho
I, host strains, and helper phage. In addition, the Lambda ZAP-CMV vector is
available in undigested form with host strains and helper phage.
cDNA Library Construction in the Lambda ZAP®-CMV Vector

Figure
3
Libraries constructed in the Lambda ZAP-CMV vector are characterized
by high titers and robust plaque size. We constructed a cDNA library in
the EcoR I and Xho I sites of the Lambda ZAP-CMV vector
using poly(A)+ RNA from human HeLa cells. This library contained approximately
3 x 106 primary plaques. The phage titer of the amplified library
was 2 x 1010 plaque-forming units (pfu)/ml. To assess the library
quality (background level and insert size), we mass excised and selected
phagemid colonies by antibiotic selection on kanamycin plates. Plasmid
DNA was prepared from 12 randomly picked colonies, and the DNA was digested
with either EcoR I and Xho I or Not I and Kpn
I restriction enzymes. All 12 clones contained a cDNA insert, ranging
in size from 0.5 kb to 2.5 kb, with an average size of 1.4 kb (Figure
3). The titer of the amplified library in the Lambda ZAP-CMV vector
remained constant upon storage at 4ºC, -80ºC, and in the presence of 7%
DMSO.
Luciferase Expression in the pCMV-Script® -EX Vector

Figure
4
To demonstrate expression levels in the pCMV-Script-EX vector, we inserted
the firefly luciferase gene into the BamH I site of the MCS. This
same luciferase gene was inserted into the parental pCMV-Script vector.
These two constructs were used for parallel transfections of Chinese hamster
ovary (CHO) cells. Cell lysates were prepared and assayed for luciferase
activity. In Figure
4, cells transfected with each construct show comparable luciferase
activity. We also detected luciferase protein in both samples by Western
blot analysis (data not shown). To further demonstrate the functionality
of the pCMV-Script-EX vector, we transfected the pCMV-Script-EX vector
with luciferase gene construct into CHO cells and selected cells with
G418 to establish a stable transfected cell line with high levels of luciferase
expression (data not shown). These data confirm that the pCMV-Script-EX
phagemid vector expresses high levels of protein in mammalian cells.
Lambda ZAP® Vectors for Diverse Applications
Table 1
Stratagene’s
Lambda ZAP ® cDNA Library Vectors
|
Comparison of Lambda cDNA Library Vectors
|
| |
HybriZAP 2.1
two-hybrid vector
|
ZAP Express
vector
|
Lambda ZAP-CMV
vector
|
Lambda ZAP II
vector
|
|
# unique cloning sites in l
(# sites in excised plasmid)
|
2
(7 in pAD-GAL4-2.1)
|
12
(17 in pBK-CMV)
|
3
(15 in pCMV-Script)
|
6
(21 in pBluescript SK- phagemid)
|
|
cloning capacity
|
6 kb
|
12 kb
|
6.5 kb
|
10 kb
|
|
eukaryotic expression
|
yes
(pADH1 promoter)
|
yes
(CMV promoter)
|
yes
(CMV promoter)
|
no
|
|
prokaryotic blue/white color screening
and b-gal fusion protein expression
|
no
|
yes
|
no
|
yes
|
|
contains excisable phagemid
|
yes
|
yes
|
yes
|
yes
|
|
antibiotic resistance
|
Ampr
|
Kanr
|
Kanr
|
Ampr
|
|
eukaryotic selection
|
leucine
|
G418
|
G418
|
none
|
|
directional cloning
|
yes
|
yes
|
yes
|
yes
|
|
suitable helper phage
|
VCSM13,
ExAssist helper phage
|
R408, RE704,
ExAssist helper phage
|
R408, RE704,
ExAssist helper phage
|
R408, VCSM13, RE704,
ExAssist helper phage
|
|
ssDNA mutagenesis
|
yes
|
yes
|
yes
|
yes
|
|
T3/T7 RNA polymerase promoters
|
T7 only
|
yes
|
yes
|
yes
|
|
exo-mung deletions
|
no
|
yes
|
yes
|
yes
|
The Lambda ZAP® vectors (Table
1) are available for prokaryotic expression (the Lambda ZAP II vector),
two-hybrid screening†† in yeast (the HybriZAP®
2.1 vector), both prokaryotic and eukaryotic expression (the ZAP Express®
vector), and now, the new Lambda ZAP-CMV vector. The Lambda ZAP II vector
is the most widely used vector for constructing cDNA libraries. Libraries
cloned in this vector can be functionally screened with nucleic acid probes
or antibodies. Alternatively, the library can be quickly and easily mass
excised into the pBluescript® SK(-) plasmid vector for analysis
of transcripts via expressed sequence tag (EST) sequencing or subtraction
and normalization procedures. The HybriZAP 2.1 vector offers the convenience
of lambda library technology; after library construction, excision of
the pAD-GAL4-2.1 plasmid vector allows cloned DNA to be screened for protein-protein
interactions in vivo. The ZAP Express vector offers library construction
with the capability for both prokaryotic and eukaryotic expression. Libraries
constructed in the ZAP Express vector can be easily screened, and individual
clones can be quickly converted to the pBK-CMV vector for eukaryotic transcription
directed by the cytomegalovirus (CMV) immediate early promoter; this results
in mid-level expression of cloned genes in mammalian cells.
Conclusions
Stratagene’s Lambda ZAP vectors are designed for simplified construction of
high-titer cDNA libraries, combined with the capability for excision and
recircularization of cloned insert DNA from lambda phage. With the simple in
vivo excision procedure, convert either individual clones or entire lambda
libraries to a plasmid format. And, the newest lambda cloning vector, the Lambda
ZAP-CMV mammalian expression vector, features the pCMV-Script-EX phagemid to
achieve the highest levels of expression in mammalian cells.
Acknowledgments
We thank members of the Research and Development group, the Vector group, and
the Custom Library group at Stratagene for discussion and suggestions.
PRODUCT LINK
REFERENCES
-
Short, J.M., et al. (1988) Nucleic Acids Res. 16:
7583-7600.
-
Alting-Mees, M., et al. (1992) Strategies 5: 58-61.
-
Alting-Mees, M. and Short, J.M. (1989) Nucleic Acids Res.
17: 9494.
-
Amberg, J., et al. (1993) Strategies 6: 2-4.
-
Mullinax, R.L. and Sorge, J.A. (1995) Strategies 8:
3-5.
-
Hosfield, T., et al. (1997) Strategies 10: 68-69.
* U.S. Patent Nos. 5,128,256 and 5,286,636 and European Patent
No. 286200
|